Efficacy Study of the Combination Mometasone + Salicylic Acid in Patients With Psoriasis

Azidus

Status and phase

Completed

Phase 3

Conditions

Psoriasis

Treatments

Drug: memotasone + salicylic acid

Study type

Interventional

Funder types

Industry

Identifiers

NCT01229085

SALMOGLEN20906

Details and patient eligibility

About

To evaluate the efficacy of the combination of mometasone furoate 0.1% and Salicylic Acid 5% in patients of both sexes who presented clinical symptoms of psoriasis of mild to moderate.

Full description

Phase III clinical trial, systematic sampling, open-label study that evaluated the efficacy of the combination of mometasone furoate 0.1% and 5% salicylic acid in 71 patients with lesions of mild to moderate psoriasis treated for up to 45 days or less than this, at the discretion of the investigator. The results were statistically analyzed and investigational data and their conclusions are referred to in this report.

Enrollment

71 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adults of both sexes, regardless of color or social class;
Age 18 or older, with good mental health;
Psoriasis patients with mild to moderate;
Patients who agreed to participate and signed the
Clarified (appendix);
Patients who agreed to return for follow-up visits.

Exclusion criteria

Patients who were making use of biologics, corticosteroids or nonsteroidal anti-inflammatory and non-steroid, or who made use of these topical medications until 15 days before inclusion or 30 days before inclusion when the administration was orally;
Patients who were exposed to the sun 15 days before the study began or during the course of the same;
Patients who were making use of acetaminophen;
Patients who did not agree to the terms described in the IC informed consent, - Patients who also had psoriatic plaques of skin disorders caused by fungi or bacteria and they were making use of antibiotic or antifungal;
Lions and other types of skin damage that was not psoriasis;
Pregnant and nursing women;
Patients using oral anticoagulants.